Recently, we have found that the activation of FGFR2 induces TNBC with multiple signaling, such as cancer stem cells (CSCs), epithelial–mesenchymal transition (EMT), and the tumor microenvironment (TME) (19). The gene discussed is FGFR2; the disease is neoplasm.